Max Hodak's Brain Revolution: Ditching Neuralink's Spikes for Biohybrid Magic
# Max Hodak's Brain Revolution: Ditching Neuralink's Spikes for Biohybrid Magic
Science Corp is on the cusp of human trials, implanting a pea-sized, 520-electrode sensor on the brain's cortex during routine surgeries like stroke ops. Led by Yale's neurosurgery chair Dr. Murat Günel, this 2027 milestone tests gentle electrical zaps to heal busted brain and spinal cells—potentially crushing multiple neurological nightmares.
Hodak, the Neuralink co-founder who bailed on Elon's crew, calls metal electrodes a dead end. They stab brains, spark damage, and crap out over time. Smart move quitting—Science's biohybrid BCIs grow lab neurons, zapped by light to bridge silicon and squishy tissue seamlessly. Preclinical mouse tests in 2024? Nailed safe implants and stimulation. This isn't Neuralink's gimmicky bypass; it's regenerative therapy, folks.
<> "Conventional probes cause brain damage that undermines long-term performance," Günel blasts. Damn right—Science's organic approach sidesteps that mess./>
Their PRIMA retinal implant proves it: 38-40 blind patients now see—one even read a novel after a decade in the dark. NEJM crowned it "the first treatment to restore vision" in advanced macular degeneration. FDA Breakthrough? Check. CE mark mid-2026? Incoming. Blueprint for cortex conquest.
Business-wise, they're loaded: $230M Series C in March 2026 rockets valuation to $1.5B (total funding $490M), 150 staff strong. Co-founder/CSO Alan Mardinly's 30-person team built this beast. Europe consumer launch before Neuralink? Bold AF, targeting treatments and enhancements like new senses. In the BCI arms race, this is the watershed: therapeutic healing trumps assistive parlor tricks, positioning Science as Neuralink's nightmare.
For devs, jackpot: Science's BCI Ecosystem hands you vertically integrated neural data tools—no custom hardware hell. PRIMA's scale-up from retina to brain screams safer, long-haul implants. Mouse data validates; human proof incoming.
Sure, Hodak's enhancement dreams (hello, super-senses) stir ethics debates amid med focus. But PRIMA's data slaps down safety skeptics. No controversies yet—just industry buzz calling this pivotal.
Opinion: Hodak's playing 4D chess. Neuralink's threads are brute force; Science is elegant evolution. If this sensor heals a single spinal injury, it rewrites neurotech. Devs, watch—biohybrids are the future stack. Time 100 Health nod? Hodak's just warming up.
